Proceeds from the round are slated to be used for product development and clinical investigation of the company’s infrared thermographic system designed for intrabody thermal measurements.
The device is intended for continuous esophageal temperature monitoring, the Cleveland, Ohio-based company said.
“We are pleased to have Boston Scientific as an investor and a representative of Boston Scientific as a board member. Securus Medical Group’s expanded investor base now includes a world-class medical device company, top-tier venture capital funds, and world-renowned healthcare systems,” president & CEO Steven Girouard said in a press release.
Boston Scientific was joined by existing investors RiverVest Venture Partners, 3X5 Special Opportunity Fund and the University of Michigan MINTS program and new investor Global Cardiovascular Innovation Center.
“This financing accelerates Securus Medical Group’s technology development, and importantly it enables further validation of the company’s core technology which holds great potential to change the standard of care for esophageal temperature monitoring,” RiverVest Venture Partners veep Karen Spilizewski said in prepared remarks.